

## Company Announcement

18 October 2010

## Novo Nordisk A/S – Share repurchase programme

On 12 August 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.0 billion in the period from 12 August 2010 to 25 October 2010.

Since the announcement as of 11 October 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,451,000		751,396,952
11 October 2010	15,000	539.5000	8,092,500
12 October 2010	30,000	544.5000	16,335,000
13 October 2010	30,000	544.7500	16,342,500
14 October 2010	45,000	540.0000	24,300,000
15 October 2010	35,000	539.1000	18,868,500
Accumulated under the programme	1,606,000		835,335,452

With the transactions stated above, Novo Nordisk owns a total of 26,484,087 treasury shares, corresponding to 4.4% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Company Announcement no 58 / 2010

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Telefax: +45 4444 6626 Internet: novonordisk.com

Page 1 of 2

CVR no: 24256790 Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <u>novonordisk.com</u>.

## Further information:

Media:

Anne Margrethe Hauge Tel: (+45) 4442 3450 amhg@novonordisk.com Investors:

Klaus Bülow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com

Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com

Jannick Lindegaard Tel: (+45) 4442 4765 jlis@novonordisk.com

In North America: Lori Moore Tel: (+1) 609 919 7991 Irmo@novonordisk.com In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com

Company Announcement no 58 / 2010

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Telefax: +45 4444 6626 Internet: novonordisk.com CVR no: 24256790

Page 2 of 2